The global anterior uveitis treatment market size is expected to reach USD 967.5 million by 2030, registering a CAGR of 12.6% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising prevalence of the disease is anticipated to aid market growth. This disease is more common when compared to panuveitis, posterior, and intermediate uveitis.

According to a 2017 article by Retina Today, this condition accounted for around 30% to 90% of the cases of uveitis. It also stated around 1% to 4% of patients experience 25% loss of visual acuity. There are different effective treatments for this disease and can be easily managed; however, it tends to recur. This disease is prevalent among both young and middle-aged group. It is also common among the geriatric population. Ocular ischemia and herpetic uveitis are the two most common causes of this disease among the geriatric population. Most of the cases occur in healthy people, however, some are associated with infectious diseases, gastrointestinal disorders, rheumatologic diseases, and lung & skin diseases. This disease is less sight-threatening as compared to posterior uveitis, however, in some cases might lead to glaucoma, cataract, and cystoid macular edema.

Request a free sample copy or view report summary: Anterior Uveitis Treatment Market Report

Anterior Uveitis Treatment Market Report Highlights

• Corticosteroids dominated the anterior uveitis treatment market in 2023 owing to its beneficial characteristic of minimizing inflammation in the eye. It is the primary treatment modality.

• Anti-TNF agents are expected to exhibit lucrative growth rate over the forecast period due to growing opportunity in treatment methods with biologic therapy using Anti-TNF drugs.

• Immunosuppressants held a significant market share in 2023 owing to their growing adoption for treatment of chronic anterior uveitis.

• Hospital pharmacies dominated the market in 2023 due to the wide treatment options available there.

• Online pharmacies are expected to witness significant CAGR over the forecast period due to convenience, ease, and availability of discounted products.

• North America held the largest revenue share in 2023 owing to high prevalence as well as healthcare expenditure in this region.

• Asia Pacific is anticipated to exhibit lucrative growth during the forecast period due to the rising number of infectious diseases in developing countries of the region and growing disposable income.

Anterior Uveitis Treatment Market Segmentation

Grand View Research has segmented the global anterior uveitis treatment market based on type, therapy, distribution channel, and region:

Anterior Uveitis Treatment Type Outlook (Revenue, USD Million, 2018 - 2030)

• Infectious Uveitis

• Non-Infectious Uveitis

  • Anterior Uveitis

  • Pan-Uveitis

  • Posterior Uveitis

  • Intermediate  Uveitis

Anterior Uveitis Treatment Therapy Outlook (Revenue, USD Million, 2018 - 2030)

• Corticosteroids

• Immunosuppressive therapies

• Biologics

• Others

• Pipeline Therapies

Anterior Uveitis Treatment Distribution Channel (Revenue, USD Million, 2018 - 2030)

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

Anterior Uveitis Treatment Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List Of Key Players Anterior Uveitis Treatment Market

• Novartis AG

• Santen Pharmaceutical Co., Ltd.

• AbbVie Inc.

• Kiora Pharmaceuticals, Inc.

• Clearside Biomedical

• Aldeyra Therapeutics, Inc.

• Aciont Inc.

• Sirion Therapeutics, Inc.

• UCB S.A.

• Lux Biosciences, Inc.

• Tarsier Pharma Ltd.